findmyKOL
Clinical trialNCT00217386CompletedPhase 2Interventional

Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes

SponsorFred Hutchinson Cancer CenterEnrollment30LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • St. Joseph Cancer Center

    Bellingham, Washington, United States

  • Olympic Medical Center

    Port Angeles, Washington, United States

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, United States

  • Seattle Cancer Care Alliance

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Mar 2004
Primary completion
31 Dec 2007
Completion
Last update posted
15 Sept 2010
Registered enrollment
30
Registry id
NCT00217386

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.